STX140, but Not Paclitaxel, Inhibits Mammary Tumour Initiation and Progression in C3(1)/SV40 T/t-Antigen Transgenic Mice

Despite paclitxael's clinical success, treating hormone-refractory breast cancer remains challenging. Paclitaxel has a poor pharmacological profile, characterized by a low therapeutic index (TIX) caused by severe dose limiting toxicities, such as neutropenia and peripheral neuropathy. Consequen...

Descripción completa

Detalles Bibliográficos
Autores principales: Meyer-Losic, Florence, Newman, Simon P., Day, Joanna M., Reed, Michael J., Kasprzyk, Philip G., Purohit, Atul, Foster, Paul A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3855596/
https://www.ncbi.nlm.nih.gov/pubmed/24324595
http://dx.doi.org/10.1371/journal.pone.0080305

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3855596/
https://www.ncbi.nlm.nih.gov/pubmed/24324595
http://dx.doi.org/10.1371/journal.pone.0080305

Ejemplares similares